See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

Y-Mabs’ IND for CD38-SADA receives FDA clearance for relapsed or refractory NHL

Oct. 18, 2023
Y-Mabs Therapeutics Inc. has received FDA clearance of its IND application for CD38-SADA, the company’s second program within its SAYA Y-PRIT (Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy) theranostic platform.
BioWorld Science Regulatory Cancer Immuno-oncology FDA IND